Skip to content

A verification study of the reduction on swollen face with the intake of lemon-derived polyphenol (enzyme-treated hesperidin): a randomized, double-blind, placebo-controlled, crossover trial

A verification study of the reduction on swollen face with the intake of lemon-derived polyphenol (enzyme-treated hesperidin): a randomized, double-blind, placebo-controlled, crossover trial - A verification study of the reduction on swollen face with the intake of lemon-derived polyphenol (enzyme-treated hesperidin)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031609
Enrollment
80
Registered
2018-03-06
Start date
2018-03-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese adult people

Interventions

[1] Duration: 2 weeks Test material: Tablets containing lemon-derived, enzyme-treated hesperidin Administration: Take one tablet after dinner * If you forget to take the tablet, take it in the day

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy Japanese adult people who are suffering from facial swelling in daily 2. Subjects who are judged as eligible to participate in the study by the physician 3. Subjects who are not detected any renal dysfunction by urinalysis at screening 4. Subjects whose systolic blood pressure is below 130 mmHg at screening 5. Within the subjects who met 2nd to 4th inclusion criteria, select subjects with relatively high score in VAS related to facial swelling at screening

Exclusion criteria

Exclusion criteria: 1. A medical history of malignant tumor, heart failure or myocardial infarction 2. Currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 3. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily 4. Currently taking medicines (include herbal medicines) and supplements 5. Subjects who are allergic to medicines and/or the test food related products * Particularly citrus fruits allergy 6. Subjects whose body mass index (BMI) is less than 18.5 kg/m2 or 30 kg/m2 or more 7. Subjects who work late-night shift or are irregular of their life-styles 8. Subjects who are pregnant, lactation, and planning to become pregnant 9. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial 10. Subjects who are judged as ineligible to participate in the study by the physician

Design outcomes

Primary

MeasureTime frame
Subjective symptoms on swollen face * Visual Analogue Scale (VAS) * Assessed the item once at screening and in the morning and evening of intervention 1 and 2 before intake and 2 weeks after intake

Secondary

MeasureTime frame
1. Wrinkles on facial skin 2. Prominences on facial skin 3. Hemoglobin concentration on facial skin 4. Melanin concentration on facial skin 5. Facial volume 6. Facial dermal water content 7. Leg volume 8. Calf circumference 9. Subjective symptoms 10. Blood pressure *1-4 Measured by ANTERA 3D *5 Measured by VECTRA H1 *6 Measured by MoistureMeter D *7 Measured leg volume by a measuring device *8 Use a measuring tape *9 Assessed subjective symptoms by VAS *1-8 Assessed the items once at screening and in the morning and evening of intervention 1 and 2 before intake and 2 weeks after intake *9 Assessed the items in the morning and evening of intervention 1 and 2 before intake and 2 weeks after intake *10 Assessed the items once at screening and in the morning of intervention 1 and 2 before intake and 2 weeks after intake

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026